enocitabine has been researched along with idarubicin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiyota, T; Kuriyama, H; Watanabe, A | 1 |
| Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS | 1 |
| Ohnishi, K; Ohno, R; Shinjyo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Ahn, YK; Cho, JG; Chung, IJ; Kim, HJ; Lee, JJ; Park, MR; Shin, DH | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Ahn, HS; Cho, B; Chung, NG; Hwang, TJ; Im, HJ; Kang, HJ; Kim, HK; Koo, HH; Kook, H; Lee, DH; Park, HJ; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Katayama, Y; Murayama, SY; Myoken, Y; Sugata, T | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, SH; Kim, YK; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, J; Shin, MG; Sohn, SK; Won, JH | 1 |
| Ahn, HK; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, KH; Kim, SH; Kim, YK; Lee, KO; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, CH; Park, J; Sohn, SK | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
1 trial(s) available for enocitabine and idarubicin
| Article | Year |
|---|---|
Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction | 1996 |
11 other study(ies) available for enocitabine and idarubicin
| Article | Year |
|---|---|
[Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Screening Assays, Antitumor; Female; Idarubicin; Leukemia P388; Mice; Neoplasm Transplantation; Tumor Cells, Cultured | 1996 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cytarabine; Daunorubicin; Ear Canal; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Radiotherapy; Recurrence; Remission Induction; Salvage Therapy; Tretinoin; Vindesine | 1997 |
Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection.
Topics: Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Citrates; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Idarubicin; Infections; Leukapheresis; Leukemia, Erythroblastic, Acute; Leukocyte Transfusion; Male; Neutropenia; Sodium Citrate; Tachycardia, Supraventricular | 2000 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Republic of Korea; Retrospective Studies; Survival Analysis; Thioguanine; Young Adult | 2010 |
Prompt and definitive diagnosis of acute invasive Aspergillus rhinosinusitis in a patient with acute myeloid leukaemia using in situ hybridization: a case report.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Cytarabine; Humans; Idarubicin; In Situ Hybridization; Itraconazole; Leukemia, Myeloid, Acute; Male; Mycological Typing Techniques; Rhinitis; Sinusitis | 2012 |
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Remission Induction; Translocation, Genetic; Young Adult | 2012 |
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Core Binding Factors; Cytarabine; Disease-Free Survival; Exons; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Korea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |